Claritas Pharmaceuticals Inc V.CLAS.H

Kaly Needs To Address Another BillionDollar Potential Market

[MinimumDamage]

More testing is required on monkeys before we can conclude that R-107 is a miracle. Now we know that R-107 is not a disaster in the sense that its not LETHAL in miniscule doses in rats and SHEEPS which is the best news since Bob sneaked this in :

April 2, 2021

Shareholders will also be asked to consider and vote on a resolution that would approve a special resolution authorizing the Company to transfer and sell to the former shareholders of Talent Biotechs Ltd. (the “Former Shareholders”) all assets of the Company’s program developing cannabidiol for the prevention and treatment of graft versus host disease (the “GVHD Program”) in consideration for the release and discharge by the Former Shareholders of all obligations the Company and its subsidiaries have to such Former Shareholders.

So GVHD is being dumped and PAH is LOADED back in the plans to addressing another Multi BILLION sector with a huge bill + royalties fees attached to it. I'm thinking that there's an actual implicit message here that this stock needs a more than just a miracle. I wonder what '' special resolution'' is in the books.

[AngelaL]

No, this is not how drug development works. R-107 successfully transited formal ("GLP") toxicology studies in rats and dogs. Such studies require the testing of doses many times in excess of the intended therapeutic dose in order to ascertain the NOAEL (no observed adverse event level). So, R-107 is safe at massive doses by definition for it to have come this far. 

[AngelaL]

Development of a small molecule such as R-107 never requires toxicology in monkeys or other primates. Tox is required in rats and one large animal species. And the large animal is dog 95% of the time and pig the other 5%. The only time monkeys are used is for large macromolecular drugs (eg proteins) where very close species resemblance to humans is essential to establish if there is a Tox problem.